Celularity (CELU) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Celularity (CELU) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, losing 73.5% versus a loss of 82.1%. Over five years, CELU leads with a -99.3% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($15.8 million vs $15.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | QNRX |
|---|---|---|
| Share price | $0.463 | $3.28 |
| Market cap | $15.02M | $15.76M |
| 1-day change | -1.05% | -2.35% |
| YTD return | -58.29% | -77.27% |
| 1-year return | -73.54% | -82.07% |
| 5-year return | -99.31% | -99.99% |
| P/E ratio (TTM) | — | 7.45 |
| EPS (TTM) | $-1.69 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $26.55M | — |
| Revenue growth (YoY) | -51.03% | — |
| Net income (latest FY) | $-91.72M | $-15.80M |
| Gross margin | 24.39% | — |
| Operating margin | -230.92% | — |
| Net margin | -345.45% | — |
| 52-week high | $2.55 | $23.50 |
| 52-week low | $0.42 | $3.18 |
| Distance from 52-week high | -81.84% | -86.04% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +565.55% |
| Average volume | 3.95M | 541.26K |
| Shares outstanding | 32.45M | 4.80M |
| Employees | 115 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
CELU vs QNRX FAQ
Which is bigger, Celularity or Quoin Pharmaceuticals?
Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $15.76M compared with $15.02M for Celularity (CELU).
Which stock has performed better over the past year, CELU or QNRX?
CELU returned -73.54% over the past 12 months, compared with -82.07% for QNRX (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.